Avista Therapeutics to Showcase Gene Therapy Advances at Major Medical Conferences
Avista Therapeutics to Showcase Gene Therapy Advances at Major Medical Conferences
Avista Therapeutics, a pioneering force in preclinical gene therapy, has recently announced its participation in several prestigious medical conferences, showcasing its innovative work in gene therapy. These events are pivotal for the company, as they facilitate the dissemination of their findings and foster collaborations with others in the medical community.
Key Presentations Scheduled
Dr. Rob Lin, the Chief Executive Officer of Avista, will lead a corporate presentation at the 2026 Cell & Gene Meeting on the Mediterranean. This conference is set to take place from April 28 to 30, 2026 in Rome, Italy. Dr. Lin's insights during the session will likely shed light on the strategic vision and pioneering research developments at Avista.
In addition, multiple abstracts from Avista have been accepted for poster presentations at two significant upcoming events:
- - The Association for Research in Vision and Ophthalmology (ARVO) from May 3 to 7, 2026 in Denver, Colorado.
- - The American Society of Gene & Cell Therapy (ASGCT) happening later, from May 11 to 15, 2026 in Boston, Massachusetts.
Highlights from ARVO Presentations
At ARVO 2026, two critical studies will be presented:
1. Abstract Title: Structural dynamics insights into principles underlying the fitness of new potent AAVs for retinal gene therapy
Presenter: Dr. Leah Byrne, Founder and Chief Scientific Officer
Session: May 5, 2026, 3:30 PM - 5:15 PM ET
Poster Board Number: 0715
Session Number: 370
Session Title: New therapeutics and delivery approaches for ocular diseases.
2. Abstract Title: Advancing gene delivery to RPE and photoreceptors via suprachoroidal injection of next-generation AAV vectors
Presenter: Dr. Laura Campello, Senior Director – Retinal Gene Therapy
Session: May 5, 2026, 3:30 PM - 5:15 PM ET
Poster Board Number: 0685
Session Number: 370
Session Title: New therapeutics and delivery approaches for ocular diseases.
Engaging with the ASGCT Community
At ASGCT 2026, Avista will feature two additional poster presentations:
- - Abstract Title: Engineered AAV2 capsids have improved performance compared to natural serotypes via intra-CSF delivery in both mouse and NHP central nervous system
Poster Reception Date: May 14, 2026, 5:00 PM - 6:30 PM ET
- - Poster Title: Manufacturability of ATX002, a Next Generation Ophthalmologic AAV Capsid
Poster Reception Date: May 14, 2026, 5:00 PM - 6:30 PM ET
About Avista Therapeutics
Founded as a collaborative effort from the University of Pittsburgh, Avista Therapeutics is at the frontier of biotechnology, primarily focusing on innovative gene therapies. Its mission revolves around overcoming challenges in delivering genetic medicines, leveraging artificial intelligence to enhance treatment efficacy. Avista aims to provide transformative therapies to patients, particularly those grappling with severe diseases affecting the retina and central nervous system. The company is also a proud member of the UPMC Enterprises portfolio, headquartered in Pittsburgh, Pennsylvania.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.